Clinical Trials Sponsored by ProLynx LLC

Total 10705 results

ProLynx LLC

Completed

A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

Neoplasms | Cancer | Tumors

United States
Institut Curie
ProLynx LLC

Not yet recruiting

A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (TOPOLOGY)

Cancer | Breast

France
Institut Curie
Merck Sharp & Dohme LLC; ProLynx LLC

Not yet recruiting

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (POP-ART)

Solid Tumor

France
Prolong Pharmaceuticals

Terminated

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Chemotherapy-induced Neutropenia

France, Netherlands
Prolong Pharmaceuticals

Withdrawn

A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients

Delayed Function of Renal Transplant
Prolong Pharmaceuticals

Completed

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer (LU)

Leg Ulcer

Dominican Republic, Panama
Progyny, Inc.

Unknown

Eeva™ Pregnancy Pilot Study (PPS) (PPS)

Infertility

United States
Progyny, Inc.

Unknown

Correlating Time-Lapse Parameters With aCGH Testing in IVF Treatment (aCGH Study)

Infertility

United States
Progyny, Inc.

Completed

Eeva 12-well Dish Study (NDS)

Infertility

United States
Prolong Pharmaceuticals

Completed

A Study of EPEG in Beta Thalassemia Patients

Beta-Thalassemia

Thailand
Prolong Pharmaceuticals

Withdrawn

Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

Sickle Cell Disease

Israel
Prolong Pharmaceuticals

Completed

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Anemia, Sickle Cell

United States
Prolong Pharmaceuticals

Completed

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

Acute Anemia

United States
Progyny, Inc.

Unknown

US Eeva™ Pregnancy Investigational Clinical Study (US EPIC) (US EPIC)

Infertility

United States
Prolong Pharmaceuticals

Terminated

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

Drug Safety

Israel
Progyny, Inc.

Completed

Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage (Eeva)

Infertility

United States
Prolong Pharmaceuticals

Completed

Safety Study of PP-007 in Subjects With Acute Ischemic Stroke (HEMERA-1)

Acute Ischemic Stroke

United States
Prolong Pharmaceuticals

Withdrawn

ANF-Rho in the Treatment of Chronic Neutropenia

Neutropenia, Severe Chronic
Prolong Pharmaceuticals

Completed

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Renal Insufficiency, Chronic

United States
Prolong Pharmaceuticals

Completed

A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients

Anemia, Sickle Cell

Colombia, Panama, Dominican Republic, Honduras
Prolong Pharmaceuticals

Completed

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

Cerebral Ischemia

United States
Prolong Pharmaceuticals

Completed

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

Delayed Function of Renal Transplant

United States
Progyny, Inc.

Completed

Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study (EPIC)

Infertility

Belgium, Netherlands
Progyny, Inc.

Unknown

Eeva System Imaging Study (PROSPECT)

Infertility

United States, New Zealand
Progyny, Inc.

Unknown

Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment (MERGE)

Infertility

United States
Progyny, Inc.

Completed

Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results (CCS)

Infertility

United States
Prolong Pharmaceuticals

Completed

Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

Sickle Cell Disease

Colombia, Panama
Progyny, Inc.

Completed

Eeva™ Continued Access Study: Assessing the Usability of Eeva in a Clinical Setting (CAS)

Infertility

United States
ProJenX
Worldwide Clinical Trials

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers (PRO-101)

Amyotrophic Lateral Sclerosis

United States
Arthritis Northwest PLLC
Epigenesys LLC

Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Arthritis, Rheumatoid

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
LLS PedAL Initiative, LLC
Kura Oncology

Not yet recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Relapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
IVFarma LLC
BridgePharm LLC; GlobalPharma LLC

Completed

Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Infertility, Female

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Monsoon Design Studio LLC
Healthark Wellness Solutions LLP

Completed

Study of Evoked Emotional Responses

Emotion, Expressed

India
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
AOBiome LLC
bioRASI, LLC

Completed

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

Atopic Dermatitis

United States
AOBiome LLC
bioRASI, LLC

Completed

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

Rosacea

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation

3

Subscribe